RxDoctor Payments Data

Douglas Ciuba, MD

Radiation Oncology · Columbus, GANPI 1427058502

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 42 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 17 manufacturers, the largest accounting for just 18.9% — the pattern of someone who eats at a lot of different presentations.

$882in general payments, 2019–2025

Across 42 payments — averaging $21.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$167
  • Boston Scientific$112
  • Sumitomo Pharma America, Inc.$109
  • Stryker$94
  • Varian Medical Systems, Inc.$64
  • Novocure Inc.$57
  • plus $279 from 11 others
$7,446in research payments, 2019–2025

Across 6 payments — averaging $1240.96 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • EMD Serono, Inc.$7K
  • Merck Kgaa$690

What the payments were for

  • Food & beverage$882100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$882 in reported general payments places this provider in the 60th percentile of 165 radiation oncology providers in Georgia.

See all radiation oncology providers in Georgia

Medicare billing

Part B allowed, 2024
$302,687
Medicare patients
282
Services billed
4,019

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SsdSilver Sulfadiazine13$385

Paid to pharmacies, not to this prescriber.

Other radiation oncology in Columbus

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →